| Similar Articles |
|---|
 |
The Motley Fool
May 26, 2010
Brian Orelli |
Is Johnson & Johnson a Buy? Let's see what it says to Congress first on safety issues.   |
The Motley Fool
June 28, 2011
Eric Bleeker |
Johnson & Johnson Is Looking Abroad for Growth Where's Johnson & Johnson generating its sales? |
The Motley Fool
December 1, 2008
Brian Orelli |
Johnson & Johnson Firms Things Up The health-care giant acquires breast-implant maker Mentor. |
The Motley Fool
July 14, 2008
Brian Orelli |
Foolish Forecast: J&J Trudges Along In advance of earnings analysts wonder if Johnson & Johnson is a recovery story waiting to happen, or still stuck in a rut? |
The Motley Fool
September 30, 2009
Brian Orelli |
Boston Scientific Pays Up And Johnson & Johnson reaps the rewards. |
Salon.com
December 22, 2000
Whit Stillman |
A preppy pantheon The film director and author of "The Last Days of Disco, With Cocktails at Petrossian Afterwards" picks five essential books for the Bass Weejuns set. |
The Motley Fool
January 26, 2010
Brian Orelli |
Is the Best of Johnson & Johnson Behind It? Johnson & Johnson announces that its sales fell for the first time in 76 years. |
The Motley Fool
July 31, 2007
Nathan Parmelee |
Break Out the Band-Aids at J&J Johnson & Johnson is making some deep cuts to change its cost structure. Shareholders haven't had much to cheer about lately here, but the potential benefits from this move could help cure some of the current softness in the business. |
The Motley Fool
August 14, 2007
Brian Orelli |
A No-Win Situation Johnson & Johnson is suing the beloved American Red Cross for trademark infringement. Johnson & Johnson just needs to walk a fine line between having its brand eroded by the Red Cross and having its brand eroded by a public relations nightmare. |
The Motley Fool
May 20, 2009
Brian Orelli |
Johnson & Johnson Tries to Pull a Travolta Johnson & Johnson seems to be making a comeback, after its drug-eluting stent market share fell precipitously to just 15% in the first quarter. |
The Motley Fool
November 26, 2010
Brian Orelli |
Get It Together, Johnson & Johnson Another day, another recall. |
The Motley Fool
July 20, 2010
Brian Orelli |
Is J&J a Bad News Buy? Another quarter in 2010, another lowered earnings guidance for Johnson & Johnson. At least the year is half over for the health-care giant. |
The Motley Fool
October 12, 2004
Alyce Lomax |
Take It Away, J&J Should investors sweat a coming slowdown in growth for pharmaceutical and consumer products giant Johnson & Johnson? |
The Motley Fool
July 12, 2011
Todd Wenning |
What Does Johnson & Johnson Do With Its Free Cash? Johnson & Johnson appears to be making fair use of its free cash flow, and its well-covered dividend may be attractive to income-focused investors. |
The Motley Fool
July 9, 2010
Brian Orelli |
Hey, Johnson & Johnson: Eight Is Enough If Johnson & Johnson can't overcome the negative image from recalls quickly, consumers will head to competing brand-name drugs or just grab generic versions of Johnson & Johnson's products. |
The Motley Fool
October 19, 2010
Brian Orelli |
Watch a 40% Decline Disappear The greatest thing going for Johnson & Johnson is its diversity in product offerings. |
The Motley Fool
August 27, 2010
Brian Orelli |
A Recall a Week, That's All We Ask For Johnson & Johnson, apparently that's too much. |
The Motley Fool
June 4, 2010
Brian Orelli |
Out With Drugs, in With Medical Devices Johnson & Johnson's movement in medical devices and diagnostics is headed in the right direction, but whether Johnson & Johnson is a buy depends a lot on how it handles its current drug problem. Unfortunately investors can't have one without the other. |
The Motley Fool
May 28, 2010
Brian Orelli |
How Much Is This Going to Cost J&J? Investors need an answer from Johnson & Johnson about low-quality drugs that were recalled. Is the problem systemic, and if so, how much will it cost the company to fix the problem? |
The Motley Fool
December 1, 2010
Brian Orelli |
We're Still Buying. Probably. Despite manufacturing problems, Johnson &Johnson continues with its purchase of Crucell. |
HBS Working Knowledge
May 15, 2006
Diane Coutu |
LBJ's Deliberate March for Power When a leader gets enough power -- when he's president of the United States or CEO of a major corporation -- then we can see what he wanted to accomplish all along. Here, a Harvard expert discusses Lyndon B. Johnson's strategy for getting close to powerful people. |
The Motley Fool
January 23, 2008
Brian Orelli |
A Dose of Stability From J&J Top-line growth looked great at Johnson & Johnson -- more than 16% year over year -- but when you dove a little further into the earnings, growth wasn't quite that stellar. |
The Motley Fool
September 27, 2010
Brian Orelli |
This Recall Is Different -- In a Good Way Johnson & Johnson strikes again, but it's not so bad this time. |
The Motley Fool
January 18, 2012 |
What Johnson & Johnson Does With Its Cash Over the last five years, Johnson & Johnson shares returned 14%, which drops to -3% without dividends -- not a bad boost to top off otherwise lowly share performance. |
The Motley Fool
June 25, 2010
Brian Orelli |
The Joys of Being Large and Diversified Johnson & Johnson's plant closure is a rounding error. |
The Motley Fool
September 14, 2009
Brian Orelli |
The Clock Is Ticking for Elan Elan is getting closer to the Sept. 26 deadline to fix its contract with Johnson & Johnson. If it doesn't, Biogen Idec has the right to take full control of Elan's and Biogen's multiple-sclerosis drug, Tysabri. |
Sports Central
October 8, 2011
David Exum |
Don't Count Out Jimmie Johnson I don't think I'll ever understand why some race fans can't embrace five-time and defending NASCAR Sprint Cup champion Jimmie Johnson. |
The Motley Fool
July 19, 2011
Brian Orelli |
J&J: Better, but Not Best A decent-looking quarter, but a turnaround could still take awhile. |
The Motley Fool
October 17, 2006
Brian Lawler |
See Johnson & Johnson Crawl Earnings growth isn't moving right along because the company has become so big. Investors, take note. |
The Motley Fool
June 15, 2011
Brian Orelli |
Johnson & Johnson Is a Quitter The diversified health-care giant has decided to exit the drug-eluting stent market. |
The Motley Fool
February 28, 2011
Brian Orelli |
Johnson & Johnson Parties Like It's 1982 The big pharma announced that it was recalling 667,632 packages of Sudafed tablets because the instructions contained a typo. |
The Motley Fool
September 28, 2009
Brian Orelli |
The Berkshire of Health Care Johnson & Johnson is becoming the Berkshire Hathaway of health care. In addition to its usual M.O. of bolt-on acquisitions, the health-care giant has recently taken some equity stakes in smaller drug companies. |
The Motley Fool
November 21, 2008
Brian Orelli |
Manufacturing Pain Johnson & Johnson has plenty of it. |
Sports Illustrated
April 11, 2001
E.M. Swift |
Setting the record straight Skier Bill Johnson reigned at more than just Sarajevo... |
The Motley Fool
August 24, 2009
Brian Orelli |
J&J Would Rather Not Say Drug delayed, reason unknown. Should shareholders be worried? It's hard to tell. |
Sports Central
March 16, 2015
Jeff Kallman |
Alex Johnson, RIP: The Fires Within To hear the Whitey Herzog say it, Johnson -- who died February 28 at 72, after a battle with cancer -- was anything but a handful, once you played things straight with him. |
The Motley Fool
August 24, 2010
Brian Orelli |
One Day, the J&J Recalls Will End Just not today. Johnson & Johnson's consumer health segment gets more than half of its sales from outside the U.S., so tainting its image outside the U.S. could be costly as well. |
The Motley Fool
October 19, 2011
Brian Orelli |
Not the Best Quarter, but... There's little reason to worry about Johnson & Johnson. |
The Motley Fool
September 14, 2007
Brian Orelli |
J&J's Expensive RNA Purchase Johnson & Johnson sets up a collaboration with Isis Pharmaceuticals to develop compounds to treat diabetes. Investors take note. |
Inc.
April 2004
Alison Stein Wellner |
Case Study Colin Johnson had a bold plan to transform his consulting firm. But when things went awry, sticking to his guns meant risking everything. |
The Motley Fool
September 25, 2009
Brian Orelli |
Oh, No! Another Tylenol Recall? Take a deep breath. Everything will be OK. |
The Motley Fool
January 8, 2008
Mac Greer |
Fool Video: The Best Stock for 2008, Buffett's Latest, and Bear Market Buys Can Apple continue to produce? Will McDonald's serve up big earnings? Is 2008 the year for Johnson & Johnson? Will Starbucks continue to yield not-so-grande returns? These and other questions are answered in this video. |
The Motley Fool
April 29, 2011
David Williamson |
Johnson & Johnson's Traumatic Purchase Johnson & Johnson agrees to purchase trauma and spine specialist Synthes. |
The Motley Fool
February 22, 2010
Brian Orelli |
So Long, See You in Arbitration After another rejection, Johnson & Johnson and Basilea call it quits. |
The Motley Fool
June 23, 2010
Brian Orelli |
Duo of Diabetes Drug Deals Make J&J Better Licensing deals add to Johnson & Johnson's diabetes franchise. |
The Motley Fool
March 17, 2009
Brian Orelli |
Stent Wars, Episode III: The Rise of Xience V Johnson & Johnson lose the lead in the stent war race, but this is a marathon, not a footrace. |
The Motley Fool
September 24, 2010
Anand Chokkavelu |
10 Core Stocks for Your Portfolio: Johnson & Johnson The health care behemoth makes the list |
The Motley Fool
December 31, 2009
Brian Orelli |
The FDA (Still) Hates Antibiotic Makers Johnson & Johnson and Basilea are the agency's latest victims. |
The Motley Fool
September 15, 2009
Brian Orelli |
What's $115 Million Between Friends? Elan has to fix the mess it had gotten itself into with its multiple sclerosis drug Tysabri. |
The Motley Fool
April 21, 2010
Brian Orelli |
Yawn! Get Back to Me Next Quarter, J&J There's more stagnant growth from the health-care giant. |
